These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 34778188)

  • 1. Atezolizumab Plus Chemotherapy vs. Chemotherapy in Advanced or Metastatic Triple-Negative Breast Cancer: A Cost-Effectiveness Analysis.
    Liu X; Lang Y; Liao Y; Zhu Y
    Front Public Health; 2021; 9():756899. PubMed ID: 34778188
    [No Abstract]   [Full Text] [Related]  

  • 2. Cost-effectiveness analysis of atezolizumab in advanced triple-negative breast cancer.
    Phua LC; Lee SC; Ng K; Abdul Aziz MI
    BMC Health Serv Res; 2020 Jun; 20(1):581. PubMed ID: 32580722
    [TBL] [Abstract][Full Text] [Related]  

  • 3. First-Line Treatment With Atezolizumab Plus Nab-Paclitaxel for Advanced Triple-Negative Breast Cancer: A Cost-Effectiveness Analysis.
    Weng X; Huang X; Li H; Lin S; Rao X; Guo X; Huang P
    Am J Clin Oncol; 2020 May; 43(5):340-348. PubMed ID: 32028340
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness Analysis of Atezolizumab Plus Nab-Paclitaxel for Advanced PD-L1 Positive Triple-Negative Breast Cancer in Japan.
    Chisaki Y; Kuwada Y; Matsumura C; Yano Y
    Clin Drug Investig; 2021 Apr; 41(4):381-389. PubMed ID: 33674955
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial.
    Schmid P; Rugo HS; Adams S; Schneeweiss A; Barrios CH; Iwata H; Diéras V; Henschel V; Molinero L; Chui SY; Maiya V; Husain A; Winer EP; Loi S; Emens LA;
    Lancet Oncol; 2020 Jan; 21(1):44-59. PubMed ID: 31786121
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of adding atezolizumab to first-line chemotherapy in patients with advanced triple-negative breast cancer.
    Wu B; Ma F
    Ther Adv Med Oncol; 2020; 12():1758835920916000. PubMed ID: 32426048
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness analysis of atezolizumab plus nab-paclitaxel for untreated metastatic triple-negative breast cancer.
    Li J; Zhang T; Lu P; Zhao J; Chen L; Jiang J
    Immunotherapy; 2020 Jul; 12(10):705-713. PubMed ID: 32522057
    [No Abstract]   [Full Text] [Related]  

  • 8. Atezolizumab (in Combination with Nab-Paclitaxel): A Review in Advanced Triple-Negative Breast Cancer.
    Kang C; Syed YY
    Drugs; 2020 Apr; 80(6):601-607. PubMed ID: 32248356
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer.
    Schmid P; Adams S; Rugo HS; Schneeweiss A; Barrios CH; Iwata H; Diéras V; Hegg R; Im SA; Shaw Wright G; Henschel V; Molinero L; Chui SY; Funke R; Husain A; Winer EP; Loi S; Emens LA;
    N Engl J Med; 2018 Nov; 379(22):2108-2121. PubMed ID: 30345906
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of pembrolizumab plus chemotherapy as first-line treatment in PD-L1-positive metastatic triple-negative breast cancer.
    Huang M; Fasching P; Haiderali A; Pan W; Gray E; Zhou ZY; Hu P; Chaudhuri M; Bailly De Tilleghem CL; Cappoen N; O'Shaughnessy J
    Immunotherapy; 2022 Sep; 14(13):1027-1041. PubMed ID: 35796042
    [No Abstract]   [Full Text] [Related]  

  • 11. Cost-effectiveness analysis of the SP142 versus 22C3 PD-L1 assays in the treatment of atezolizumab plus
    Shimabukuro Ho R; Mioti Sebastião M; Venezian de Carvalho JP; Neves T; Nussbaum M
    J Med Econ; 2020 Nov; 23(11):1340-1344. PubMed ID: 32897765
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Economic Evaluation of Cisplatin Plus Gemcitabine Versus Paclitaxel Plus Gemcitabine for the Treatment of First-Line Advanced Metastatic Triple-Negative Breast Cancer in China: Using Markov Model and Partitioned Survival Model.
    Rui M; Shi F; Shang Y; Meng R; Li H
    Adv Ther; 2020 Sep; 37(9):3761-3774. PubMed ID: 32647912
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Subgroup analysis of Japanese patients in a Phase 3 study of atezolizumab in advanced triple-negative breast cancer (IMpassion130).
    Iwata H; Inoue K; Kaneko K; Ito Y; Tsugawa K; Hasegawa A; Nakagawa S; Kuratomi H; Tamura K
    Jpn J Clin Oncol; 2019 Dec; 49(12):1083-1091. PubMed ID: 31612909
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of atezolizumab plus chemotherapy for advanced non-small-cell lung cancer.
    Lin S; Luo S; Zhong L; Lai S; Zeng D; Rao X; Huang P; Weng X
    Int J Clin Pharm; 2020 Aug; 42(4):1175-1183. PubMed ID: 32524512
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer.
    Miles D; Gligorov J; André F; Cameron D; Schneeweiss A; Barrios C; Xu B; Wardley A; Kaen D; Andrade L; Semiglazov V; Reinisch M; Patel S; Patre M; Morales L; Patel SL; Kaul M; Barata T; O'Shaughnessy J;
    Ann Oncol; 2021 Aug; 32(8):994-1004. PubMed ID: 34219000
    [TBL] [Abstract][Full Text] [Related]  

  • 16. First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis.
    Emens LA; Adams S; Barrios CH; Diéras V; Iwata H; Loi S; Rugo HS; Schneeweiss A; Winer EP; Patel S; Henschel V; Swat A; Kaul M; Molinero L; Patel S; Chui SY; Schmid P
    Ann Oncol; 2021 Aug; 32(8):983-993. PubMed ID: 34272041
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of Atezolizumab Combination Therapy for First-Line Treatment of Metastatic Nonsquamous Non-Small Cell Lung Cancer in the United States.
    Criss SD; Mooradian MJ; Watson TR; Gainor JF; Reynolds KL; Kong CY
    JAMA Netw Open; 2019 Sep; 2(9):e1911952. PubMed ID: 31553470
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial.
    Mittendorf EA; Zhang H; Barrios CH; Saji S; Jung KH; Hegg R; Koehler A; Sohn J; Iwata H; Telli ML; Ferrario C; Punie K; Penault-Llorca F; Patel S; Duc AN; Liste-Hermoso M; Maiya V; Molinero L; Chui SY; Harbeck N
    Lancet; 2020 Oct; 396(10257):1090-1100. PubMed ID: 32966830
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patient-reported outcomes from the phase III IMpassion130 trial of atezolizumab plus nab-paclitaxel in metastatic triple-negative breast cancer.
    Adams S; Diéras V; Barrios CH; Winer EP; Schneeweiss A; Iwata H; Loi S; Patel S; Henschel V; Chui SY; Rugo HS; Emens LA; Schmid P
    Ann Oncol; 2020 May; 31(5):582-589. PubMed ID: 32178964
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Atezolizumab in the treatment of metastatic triple-negative breast cancer.
    Pérez-García J; Soberino J; Racca F; Gion M; Stradella A; Cortés J
    Expert Opin Biol Ther; 2020 Sep; 20(9):981-989. PubMed ID: 32450725
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.